Video RFK Jr’s go-to diet food...sauerkraut? Fox News host Jimmy Failla discusses Health and Human Services Secretary Robert F. Kennedy Jr.'s promotion of fermented foods on ‘America Reports.’
America should continue to lead the world in clinical research and medical innovation.
A recent study found that China now conducts more early-stage clinical trials than the United States. In 2025, Chinese companies accounted for nearly half of global pharmaceutical licensing deal activity. Those trends should concern every American.
For nearly 80 years, clinical trials have driven medical progress. They transform scientific discoveries into treatments that save lives. They establish whether new therapies are safe and effective. They generate the evidence that physicians, patients, and regulators use to make decisions.
LIZ PEEK: TRUMP MUST STAY STRONG, US RELIANCE ON CHINESE MINERALS AND DRUGS PUTS AMERICANS AT RISK
But clinical trials do more than generate evidence.
They attract investment, scientific talent, and the infrastructure that supports future innovation.
When clinical research moves overseas, those advantages often move with it.
Early-stage clinical trials matter because they determine where new technologies are tested, refined, and validated. They influence where companies expand, where expertise develops, and which countries will lead the next generation of medical innovation.
The United States cannot afford to surrender this strategic advantage.
Clinical research creates high-skilled jobs, gives patients earlier access to innovative therapies, and strengthens a sector that directly affects economic prosperity, public health, and national security.
America should not lose clinical research because of barriers that we have the power to remove.
Under President Trump's leadership, the Department of Health and Human Services is taking action.
Today, FDA, NIH, CMS, ONC, ARPA-H, and the HHS Office of Inspector General launched a coordinated effort to strengthen America's clinical research enterprise and bring more clinical research and investment back to the United States.
At FDA, Acting Commissioner Kyle Diamantas and career leadership are clarifying expectations for sponsors, streamlining Phase 1 development, and developing a pilot program to accelerate early-stage clinical trials. FDA estimates these changes could reduce development timelines by 6 to 12 months. The agency has also clarified that, in many cases, one high-quality clinical trial supported by confirmatory evidence may provide the basis for approval.
At NIH, Director Jay Bhattacharya is strengthening support for informative, well-powered clinical trials while advancing artificial intelligence, human cell-based models, real-world data, and other tools that can move promising therapies to patients more efficiently. NIH researchers are also applying lessons from pioneering personalized gene-editing therapies and working to streamline cancer clinical trials and improve enrollment.
The Office of the National Coordinator is working to connect more eligible patients with clinical trials through electronic health records and other digital tools integrated into routine care.
FDA LAUNCHES NEW AI-POWERED SYSTEM TO TRACK DRUG AND VACCINE SIDE EFFECTS NATIONWIDE
ARPA-H is developing technologies that identify promising therapies earlier, predict safety issues sooner, improve trial design, and reduce development costs.
The HHS Office of Inspector General is seeking public input on whether existing regulations create unnecessary obstacles to compensating clinical trial participants while preserving safeguards against fraud and abuse.
These efforts pursue a straightforward objective: make the United States the best place in the world to conduct clinical research and develop new medicines.
CLICK HERE FOR MORE FOX NEWS OPINION
Government cannot achieve that goal alone. Researchers, health systems, academic medical centers, technology companies, contract research organizations, and pharmaceutical developers all have a role to play. If regulations, contracting requirements, or institutional practices are slowing research without improving safety, we want to hear about them. We are prepared to challenge assumptions and remove barriers that no longer serve patients, science, or the public interest.
At the same time, we will protect the principles that matter most. Patients deserve transparency, informed consent, and confidence that medical decisions rest on rigorous scientific evidence. We can accelerate clinical research without compromising scientific and ethical integrity.
Under President Trump's leadership, HHS is restoring America's position in clinical research.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
We are modernizing outdated processes that slow innovation and rebuilding the foundation for the next generation of medical breakthroughs.
We will continue to innovate. We will continue to lead.
CLICK HERE TO READ MORE FROM ROBERT F. KENNEDY JR.
Robert F. Kennedy Jr. is the 26th Secretary of the U.S. Department of Health and Human Services.
